medigraphic.com

2013, Number 1

<< Back Next >>

Rev Hematol Mex 2013; 14 (1)

Correlation between age and white blood cell count at diagnosis in patients with acute leukemia

Ramírez-Duarte S, Santoyo-Sánchez A, Collazo-Jaloma J, Salinas-Meritú I, Díaz-Estrada I, Martínez-Murillo C, Ramos-Peñafiel C

Language: Spanish
References: 20
Page: 9-14
PDF size: 756.69 Kb.


ABSTRACT

Background: Acute leukemia is the most common cause of cancerrelated death Many variables impact on the prognosis, but age and white blood count are the most important.
Material and methods: Cross-sectional study conducted in patients with diagnosis of acute leukemia in the Hospital General de México and the Hospital General de Cuautitlan between 2006 -2012. Statistical Analysis. Pearson correlation test and lineal regression between age and White blood count at the diagnosis. T- test for the mean difference between White blood count of acute lymphoid and acute myeloid leukemia.
Results: 441 were studied, mostly acute lymphoblastic leukemia (N=279,63.3%) followed by acute myelomonoblastic leukemia (n=65,14.7%) and acute myeloid leukemia with maturation. (n=44, 10%). The median white blood cell count at the diagnosis was 44 x 103/mcL (3.1- 682 x 103/mcL). There were differences between the median white blood cell count at the diagnosis between both leukemias (105.08 x 103/mcL versus 72.51 x 103/mcL, p=0.009, 95% IC (range 8.26- 56.88)]. There was no significant difference in the Pearson correlation test ((p=0.925,95%IC). The R square of the linear regression was 0.005 and 0.000 for acute lymphoblastic leukemia and acute myeloblastic leukemia respectively, with no specific relationship.
Conclusion: Age and White blood count are uncorrelated independent variables. The distribution of the different types of leukemia according to age is the same as other series, hyperleukocytosis is the most common manifestation of acute leukemia.


REFERENCES

  1. Tirado-Gómez L, Mohar-Betancourt A. Epidemiología de las Neoplasias Hemato-Oncológicas. Cancerología 2007(2):109-120.

  2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-5039.

  3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood Journal 2009;114:937-951.

  4. Arber DA. Realistic pathologic classification of acute myeloid leukemias. Am J Clin Pathol 2001;115:552-560.

  5. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012;119:34 -43.

  6. Ganzel C, Rowe JM. Prognostic factors in adult acute leukemia. Hematol Oncol Clin North Am 2011;25:1163-1187.

  7. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012;26:117-122.

  8. Majhail NS, Lichtin AE. Acute leukemia with a very high leukocyte count: confronting a medical emergency. Cleve Clin J Med 2004;71:633-637.

  9. Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. Leukocytoreduction for acute leukemia. Ther Apher 2002;6:15-23.

  10. Creutzig U, Ritter J, Ludwig WD, Harbott J, Löffler H, Schellong G. [Classification of AML by morphologic, immunologic and cytogenetic criteria. Review with reference to subtypes in the AML-BFM-87 study. Klin Pediatr 1993;205:272-280.

  11. Rego MF, Pinheiro GS, Metze K, Lorand-Metze I. Acute leukemias in Piauí: comparison with features observed in other regions of Brazil. Braz J Med Biol Res 2003;36:331-337.

  12. Callera F, Mulin CC, Rosa ES, Melo DB, Melo CM. High prevalence of morphological subtype FAB M1 in adults with de novo acute myeloid leukemia in São José dos Campos, São Paulo. Sao Paulo Med J 2006;124:45-47.

  13. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002;99:863-871.

  14. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011;2011:43-50.

  15. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29(5):551-565.

  16. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760-3767.

  17. Thomas D. Childhood Philadelphia-chromosome-positive Blymphoblastic leukaemia. Lancet Oncol 2012;13:860-862.

  18. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, et al. Acute lymphoblastic leukemia. J Natl Compr Canc Netw 2012;10(7):858-914.

  19. Van Zant G, Liang Y. Concise review: hematopoietic stem cell aging, life span, and transplantation. Stem Cells Transl Med 2012;1(9):651-657.

  20. Pawelec G. Hallmarks of human “immunosenescence”: adaptation or dysregulation? Immun Ageing 2012;9(1):15.




2020     |     www.medigraphic.com